Dariohealth vs Sophia Genetics SA
Sophia Genetics SA is the larger business, with $77.3m of revenue in fiscal 2025 against $22.4m for Dariohealth (3.5 times as much). Sophia Genetics SA grew faster (18.6% against -17.3%). Sophia Genetics SA kept more of each dollar of sales as profit: a net margin of -102.2% against -186.6%. Dariohealth carries less debt relative to equity (45.3% against 101.2%).
| Latest fiscal year | DariohealthDRIO, 2025 | Sophia Genetics SASOPH, 2025 |
|---|---|---|
| Revenue | $22.4m | $77.3m |
| Revenue growth | -17.3% | 18.6% |
| Net income | −$41.7m | −$79.0m |
| Operating margin | -163.9% | -91.8% |
| Net margin | -186.6% | -102.2% |
| Return on equity | -59.6% | -110.0% |
| Free cash flow | −$26.1m | −$36.5m |
| Cash | $21.8m | $70.3m |
| Total debt | $30.7m | $47.7m |
| Debt to equity | 45.3% | 101.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 160 | — |
| Market value | $22.2m | $460m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 1 buys, 0 sales | 1 buys, 150 sales |